시장보고서
상품코드
1309723

세계의 특수 제네릭 시장 규모, 점유율, 산업 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별 전망과 예측(2023-2030년)

Global Specialty Generics Market Size, Share & Industry Trends Analysis Report By Type, By Application, By End Use, By Regional Outlook and Forecast, 2023 - 2030

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 233 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 특수 제네릭(Specialty Generics) 시장 규모는 2030년 1,415억 달러에 이를 전망이며, 9.8%의 CAGR로 성장하여 상승할 것으로 예측됩니다.

KBV Cardinal 매트릭스에 제시된 분석에 따르면, Novartis AG는 시장 최고의 러너입니다. 2020년 9월 노바티스는 아프리카 의료 공급 플랫폼을 통해 아프리카 연합과 협력했습니다. 이 제휴는 노바티스 유행 대응 제품 AU 회원국과 캘리콤 국가로 의약품 공급을 강화합니다. Viatris, Inc., Dr. Reddy"s Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Fresenius SE& Co. KGaA, Hikma Pharmaceuticals PLC 등이 시장 주요 혁신가입니다.

시장 성장 요인

고령화 인구 증가

WHO 보고서에 따르면 사람들은 전반적으로 오래 살고 있습니다. 현재 대다수 사람들이 60대 이후까지 살 것을 계획하고 있습니다. 2030년 6명 중 1명이 60세 이상입니다. 2020년 10억명으로 최근에는 14억명이 60세 이상에 달했습니다. 2050년 60세 이상 인구가 21억 명이 됩니다. 예측에 따르면 2050년 80세 이상 노인은 4억 2,600만 명이 됩니다. 2050년 저, 중소득국가 세계의 60세 이상 인구 3분의 2를 차지하게 됩니다. 사람들이 오랫동안 살고만성 질환과 암과 같은 더 심각한 문제를 견디게 되면서, 전문성이 높은 제네릭 의약품 요구가 높아질 전망입니다.

건강 관리 지출 증가

각국 정부 건강 관리 산업 투자 건수와 규모 증가는 시장 성장의 주요 촉진 요인 중 하나입니다. WHO 보고에 따르면, 모든 소득 수준 정부가 의료 지출 급격한 증가로 의료 지출은 미국 과거 최고 9조 달러(세계의 GDP 약 11%)에 도달했습니다. 일반적으로 정부 의료 지출 증가는 개인 지출 감소를 거의 상쇄합니다. 의료 산업 지출 증가는 시장 기술 혁신 증가로 이어지고 있습니다. 헬스케어 산업 투자가 증가한 결과 시장이 확대됩니다.

시장 성장 억제 요인

시장 성장을 방해하는 규제 문제

전문성 제약은 복잡성과 특징적인 투여 방식으로 인해 규제에 주의해야 할 수도 있습니다. 이러한 제네릭 의약품은 고액으로 시간이 많이 걸리는 약사 승인이 필요할 수 있습니다. 시장 진입 지연 및 규제 장애로 인해 시장 확대가 방해될 수 있습니다. 전문성 제약은 현행 법률 및 승인 프로세스에 잘 맞지 않을 수 있습니다. 이러한 복잡한 품목을 다루기 위해서는 규제 당국이 규제를 수정하거나 새로운 절차를 만들 필요가 있을 수 있습니다. 결과적으로 승인 프로세스가 장기화되고 생산자에게 불확실성이 증가하여 전문성 제네릭 생산이 지연될 수 있습니다.

유형 전망

유형별로 시장은 주사제, 경구제 등으로 분류됩니다. 2022년 주사제 부문이 최대 판매 점유율을 차지하고 시장을 독점했습니다. 이 분야는 흡수가 빨리 효과가 장시간 지속되는 등 주사제 이점이 환자 컴플라이언스와 수용성을 높이고 있기 때문이라고 생각됩니다. 특수 주사용 제네릭 의약품으로 알려진 약물 요법은 제네릭 의약품으로 입수할 수 있으며, 점적, 주사, 흡입 투여가 필요한만성 질환 치료에 이용됩니다. 선발품과 동일한 활성 성분을 가지며 다양한 약물 치료에 사용되는 생물 제제도 포함됩니다.

용도별 전망

용도에 따라 시장은 종양, 염증성 질환, 다발성 경화증, C형 간염 등으로 구분됩니다. C형 간염 부문은 2022년 현저한 수익 점유율을 기록했습니다. C형 간염 감염 대부분은 위험한 주사 기술, 스크리닝되지 않은 수혈, 위험한 의료 치료, 약물 주사, 혈액에 노출되는 성행위 등으로 인한 혈액 노출에 기인합니다. C형 간염 바이러스 신규 감염자는 매년 약 150만 명이 보고되고 있으며, 세계적으로 추정 5,800만 명이 감염됩니다. 추계에 따르면 세계에서 320만 명의 어린이와 청소년이 C형 만성 간염에 감염되었다고 합니다.

최종 용도, 전망

최종 용도별로 시장은 전문 약국, 소매 약국, 병원 약국으로 세분화되며 2022년 전문 약국 부문시장 가장 큰 매출 점유율을 차지합니다. 전문 약국은 유통 비용이 낮고 의약품 액세스가 편리하기 때문에 주요 전문 제네릭 의약품 제조업체와 보험 회사는 제품 유통을 위해 전문 약국을 선택합니다. 또한 브랜드 제품에 비해 전문성 제약 제품 재고가 저비용이기 때문에 투자 수익률이 높습니다. 전문 약국 환자 접근 극대화, 적시 배달, 효율적인 유통 관리는 모두 소비자를 유치하여 시장 부문 확대에 기여합니다.

지역별 전망

지역별로 시장은 북미, 유럽, 아시아태평양, LAMEA로 나뉩니다. 2022년 북미가 시장 가장 높은 수익 점유율을 획득하여 시장을 선도했습니다. 이는 혁신적인 제품 승인에 유리한 규제 정책이 있기 때문입니다. 미국 FDA는 전체 승인 절차를 간소화하기 위해 몇 가지 시도를 시작했습니다. 그러므로 주요 제조업체들은 전문성 제약을 시장에 투입하기 위해 계속 노력하고 있습니다.

목차

제1장 시장 범위와 조사 방법

  • 시장 정의
  • 목적
  • 시장 범위
  • 세분화
  • 조사 방법

제2장 시장 주요 요약

  • 소개
    • 주요 요약
      • 시장구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 성장 촉진 요인
    • 시장 성장 억제 요인

제3장 경쟁 분석

  • KBV Cardinal Matrix
  • 최근 업계 전체 전략 전개
    • 파트너십, 협업 및 계약
    • 제품 출시 및 제품 확대
    • 인수와 합병
    • 승인 및 평가판
  • 주요 성공 전략
    • 주요 전략
    • 주요 전략 움직임

제4장 세계의 스페셜티 제네릭 시장 : 유형별

  • 세계의 주사제 시장 : 지역별
  • 세계의 경구약 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제5장 세계의 스페셜티 제네릭 시장 : 용도별

  • 세계의 염증 상황 시장 : 지역별
  • 세계의 다발성 경화증 시장 : 지역별
  • 세계의 C형 간염 시장 : 지역별
  • 세계의 종양학 시장 : 지역별
  • 세계의 기타 시장 : 지역별

제6장 세계의 스페셜티 제네릭 시장 : 최종 용도별

  • 세계의 전문 약국 시장 : 지역별
  • 세계의 소매 약국 시장 : 지역별
  • 세계의 병원 약국 시장 : 지역별

제7장 세계의 스페셜티 제네릭 시장 : 지역별

  • 북미
    • 북미 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미
  • 유럽
    • 유럽 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽
  • 아시아태평양
    • 아시아태평양 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아태평양
  • 라틴아메리카, 중동, 아프리카
    • 라틴아메리카, 중동, 아프리카 시장 : 국가별
      • 브라질
      • 아르헨티나
      • 아랍에미리트(UAE)
      • 사우디아라비아
      • 남아프리카
      • 나이지리아
      • 기타 라틴아메리카, 중동, 아프리카

제8장 기업 프로필

  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd
  • Fresenius SE& Co KGaA
  • Dr Reddy"s Laboratories Ltd.
  • Mallinckrodt PLC
  • Bausch Health Companies, Inc
  • Viatris, Inc
  • Apotex, Inc
NJH 23.08.24

The Global Specialty Generics Market size is expected to reach $141.5 billion by 2030, rising at a market growth of 9.8% CAGR during the forecast period.

Oncology is one of the major application specialty generics, thereby, it generated $10,292 million revenue in the market in 2022. Cancer will be the primary cause of nearly 10 million deaths in 2020, or close to one in every six. About 30% of cancer cases in low- and lower-middle-income nations are caused by cancer-causing diseases such as the human papillomavirus (HPV) and hepatitis. Many cancers are curable if caught early and treated successfully, but due to the adoption of a Western lifestyle, heavy alcohol and tobacco use, bad dietary habits, and lack of physical activity. The market is expected to see increased demand as cancer cases rise.

The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In January, 2023, Sun Pharmaceutical Industries rolled out the generic version of palbociclib, a breast cancer medication by Pfizer. The launch would be under the brand name Paleno, which would address the treatment requirements of several advanced breast cancer patients in India. Additionally, In July, 2022, Dr Reddy's Laboratories announced the launch of the generic version Bortezomib for Injection, the medication of Velcade brand. The product launch can be used for the treatment of certain types of cancer across the US market. The product can be delivered in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous.

Based on the Analysis presented in the KBV Cardinal matrix; Novartis AG are the forerunners in the Market. In September, 2020, Novartis collaborated with the African Union through the Africa Medical Supplies Platform. This collaboration would enhance the supply of medicines from the Novartis Pandemic Response offering to the AU member states and Caricom countries. Companies such as Viatris, Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Fresenius SE & Co. KGaA and Hikma Pharmaceuticals PLC are some of the key innovators in the Market.

Market Growth Factors

Growing ageing population.

The WHO reports that people are living longer overall. The majority of people today likely plan to live until their sixties and beyond. By 2030, one in six people will be 60 years of age or older. 1.4 billion people will be above the age of 60 by this time, up from 1 billion in 2020. By 2050, there will be 2.1 billion people in the globe who are 60 years of age or older. According to projections, there will be 426 million individuals who are 80 years of age or older by the year 2050. By 2050, low- and middle-income countries will be home to two-thirds of the world's over-60 population. The need for specialty generics will rise as people live longer and endure more severe problems like chronic illnesses and cancer.

Growing healthcare expenditures

The increasing number & size of investments invested in the healthcare industry by governments of different nations is one of the primary drivers of the market's growth. The WHO reports that healthcare spending reached a record high of US $9 trillion (about 11% of global GDP) due to substantial increases in healthcare spending by governments at all income levels. In general, rising government health spending largely offsets declining personal spending. Increasing spending in the healthcare industry has led to an increase in market innovations. The market is expanding as a result of increased investment in the healthcare industry.

Market Restraining Factors

Regulatory challenges impeding market growth

Due to their complexity or distinctive delivery methods, specialty generics may need more regulatory attention. These items may require expensive and time-consuming regulatory approval. Market entrance delays and regulatory obstacles can prevent the market from expanding. Specialty generics might not cleanly fit into current legislative or approval processes. In order to handle these complicated items, regulatory bodies may need to modify their regulations or create new procedures. This might delay the launch of specialty generics by making the approval process take longer and creating more uncertainty for producers.

Type Outlook

On the basis of type, the market is classified into injectables, oral drugs and others. In 2022, the injectables segment dominated the market with the maximum revenue share. The segment's growth can be ascribed to the advantages of injectables, such as their quick absorption and long-lasting effects, which increase patient compliance and acceptability. Drug therapies known as specialty injectable generics are available as generics and are utilized to treat chronic conditions that must be administered via infusion, injection, or inhalation. It has the same active ingredients as the branded versions of it and includes biologics that are used to treat various medications.

Application Outlook

Based on application, the market is segmented into oncology, inflammatory conditions, multiple sclerosis, hepatitis C, and others. The hepatitis C segment recorded a remarkable revenue share in the in 2022. Most hepatitis C infections result from exposure to blood from risky injection techniques, unscreened blood transfusions, risky medical procedures, injecting drugs, and sexual behaviors that expose one to blood. Around 1.5 million new cases of the hepatitis C virus are reported each year, with an estimated 58 million people worldwide carrying the infection. According to estimates, 3.2 million children and adolescents worldwide have chronic hepatitis C infection.

End use Outlook

By end use, the market is fragmented into specialty pharmacy, retail pharmacy, and hospital pharmacy. In 2022, the specialty pharmacy segment witnessed the largest revenue share in the market. Because specialty pharmacies have low distribution costs and convenient access to medications, major specialty generic manufacturers & insurance companies choose them for product distribution. In addition, in comparison to branded products, specialty generic drug inventory's low cost offers a better return on investment. Maximizing patient access, timely delivery, and efficient distribution management of specialty pharmacies all draw consumers to them and thus contribute to the expansion of this market segment.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North American region led the market by generating the highest revenue share in the market. This is due to the existence of regulatory policies that are favorable to the approval of innovative products. The American FDA has launched several attempts to streamline the entire approval procedure. Therefore, the major producers continuously work to commercialize specialty generic medicines on the market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Novartis AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Ltd., Mallinckrodt PLC, Bausch Health Companies, Inc., Viatris, Inc. and Apotex, Inc.

Recent Strategies Deployed in Specialty Generics Market

Partnerships, Collaborations and Agreements:

Mar-2022: Viatris Inc. partnered with Kindeva Drug Delivery L.P., a developer and manufacturer of products across a wide range of complex drug-delivery formats. Under this partnership, both companies received FDA approval for Breyna, the generic version of AstraZeneca's Symbicort. The Bryna is a drug-device combined product that is indicated for various patients with asthma or chronic obstructive pulmonary disease and would be available in 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.

Sep-2021: Hikma Pharmaceuticals PLC signed an agreement with FAES Farma S.A., a manufacturer, and developer of commercialized pharmaceutical products. Under this agreement, both companies would aim to market and sell Bilastine tablets which is a non-sedating second-generation antihistamine molecule for the treatment of allergic rhinitis and urticaria.

Product Launches and Product Expansions:

Jan-2023: Sun Pharmaceutical Industries rolled out the generic version of palbociclib, a breast cancer medication by Pfizer. The launch would be under the brand name Paleno, which would address the treatment requirements of several advanced breast cancer patients in India.

Jan-2023: Hikma Pharmaceuticals PLC released an authorized generic version of Jazz Pharmaceuticals' Xyrem oral solution, a prescription medicine for narcolepsy symptoms in people of 7 years or older. This launch broadens Hikma's diversified offering of generic products and emphasizes its capability to reach millions of people relying on Hikma's medicines.

Jan-2023: Hikma Pharmaceuticals PLC rolled out the Naloxone Hydrochloride Injection, USP, 2mg/2mL, in the prefilled syringe (PFS) form across the US. This would be the third PFS product launch that can be used for the emergency treatment of a known or expected opioid overdose.

Jul-2022: Dr Reddy's Laboratories announced the launch of the generic version Bortezomib for Injection, the medication of Velcade brand. The product launch can be used for the treatment of certain types of cancer across the US market. The product can be delivered in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous.

Mar-2022: Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. introduced a generic version of Revlimid1, the medication in 5mg, 10mg, 15mg, and 25mg strengths across the United States. The launched product aims to deliver patients with another key treatment alternative for highly challenging conditions, indicating Teva's adherence to making complex generic drugs accessible to patients who require a generic version of Revlimid.

May-2021: Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., unveiled the generic version of THIOLA tablets, the medication for use in combination with high fluid intake, alkali, and diet modification. The launched generic version is unresponsive to treatment with alkali, high fluid intake, and diet modification.

Acquisitions and Mergers:

Mar-2022: Fresenius completed the acquisition of mAbxience, a leading international biopharmaceutical company. The acquisition aimed at expanding its business by making cheaper versions of biotechnology drugs that have lost patent protection. Also, the acquisition would further strengthen and leverage Fresenius Kabi's position, as both perfectly complement the company's growth businesses in biopharmaceuticals & medical technology.

Approvals and Trials:

Sep-2022: Bausch Health Companies Inc. came into partnership with Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. Through this partnership, both companies would unveil RYALTRIS which received approval from Health Canada for the symptomatic treatment of moderate to critical seasonal allergic rhinitis and associated ocular symptoms in children aged 6 years and more.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Injectables
  • Oral Drugs
  • Others

By Application

  • Inflammatory conditions
  • Multiple sclerosis
  • Hepatitis C
  • Oncology
  • Others

By End Use

  • Specialty Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius SE & Co. KGaA
  • Dr. Reddy's Laboratories Ltd.
  • Mallinckrodt PLC
  • Bausch Health Companies, Inc.
  • Viatris, Inc.
  • Apotex, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Specialty Generics Market, by Type
    • 1.4.2 Global Specialty Generics Market, by Application
    • 1.4.3 Global Specialty Generics Market, by End Use
    • 1.4.4 Global Specialty Generics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Approvals and Trials
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
    • 3.3.2 Key Strategic Move: (Product Launches and Product Expansions: 2020, May - 2023, Jan) Leading Players

Chapter 4. Global Specialty Generics Market by Type

  • 4.1 Global Injectables Market by Region
  • 4.2 Global Oral Drugs Market by Region
  • 4.3 Global Others Market by Region

Chapter 5. Global Specialty Generics Market by Application

  • 5.1 Global Inflammatory conditions Market by Region
  • 5.2 Global Multiple sclerosis Market by Region
  • 5.3 Global Hepatitis C Market by Region
  • 5.4 Global Oncology Market by Region
  • 5.5 Global Others Market by Region

Chapter 6. Global Specialty Generics Market by End Use

  • 6.1 Global Specialty Pharmacy Market by Region
  • 6.2 Global Retail Pharmacy Market by Region
  • 6.3 Global Hospital Pharmacy Market by Region

Chapter 7. Global Specialty Generics Market by Region

  • 7.1 North America Specialty Generics Market
    • 7.1.1 North America Specialty Generics Market by Type
      • 7.1.1.1 North America Injectables Market by Country
      • 7.1.1.2 North America Oral Drugs Market by Country
      • 7.1.1.3 North America Others Market by Country
    • 7.1.2 North America Specialty Generics Market by Application
      • 7.1.2.1 North America Inflammatory conditions Market by Country
      • 7.1.2.2 North America Multiple sclerosis Market by Country
      • 7.1.2.3 North America Hepatitis C Market by Country
      • 7.1.2.4 North America Oncology Market by Country
      • 7.1.2.5 North America Others Market by Country
    • 7.1.3 North America Specialty Generics Market by End Use
      • 7.1.3.1 North America Specialty Pharmacy Market by Country
      • 7.1.3.2 North America Retail Pharmacy Market by Country
      • 7.1.3.3 North America Hospital Pharmacy Market by Country
    • 7.1.4 North America Specialty Generics Market by Country
      • 7.1.4.1 US Specialty Generics Market
        • 7.1.4.1.1 US Specialty Generics Market by Type
        • 7.1.4.1.2 US Specialty Generics Market by Application
        • 7.1.4.1.3 US Specialty Generics Market by End Use
      • 7.1.4.2 Canada Specialty Generics Market
        • 7.1.4.2.1 Canada Specialty Generics Market by Type
        • 7.1.4.2.2 Canada Specialty Generics Market by Application
        • 7.1.4.2.3 Canada Specialty Generics Market by End Use
      • 7.1.4.3 Mexico Specialty Generics Market
        • 7.1.4.3.1 Mexico Specialty Generics Market by Type
        • 7.1.4.3.2 Mexico Specialty Generics Market by Application
        • 7.1.4.3.3 Mexico Specialty Generics Market by End Use
      • 7.1.4.4 Rest of North America Specialty Generics Market
        • 7.1.4.4.1 Rest of North America Specialty Generics Market by Type
        • 7.1.4.4.2 Rest of North America Specialty Generics Market by Application
        • 7.1.4.4.3 Rest of North America Specialty Generics Market by End Use
  • 7.2 Europe Specialty Generics Market
    • 7.2.1 Europe Specialty Generics Market by Type
      • 7.2.1.1 Europe Injectables Market by Country
      • 7.2.1.2 Europe Oral Drugs Market by Country
      • 7.2.1.3 Europe Others Market by Country
    • 7.2.2 Europe Specialty Generics Market by Application
      • 7.2.2.1 Europe Inflammatory conditions Market by Country
      • 7.2.2.2 Europe Multiple sclerosis Market by Country
      • 7.2.2.3 Europe Hepatitis C Market by Country
      • 7.2.2.4 Europe Oncology Market by Country
      • 7.2.2.5 Europe Others Market by Country
    • 7.2.3 Europe Specialty Generics Market by End Use
      • 7.2.3.1 Europe Specialty Pharmacy Market by Country
      • 7.2.3.2 Europe Retail Pharmacy Market by Country
      • 7.2.3.3 Europe Hospital Pharmacy Market by Country
    • 7.2.4 Europe Specialty Generics Market by Country
      • 7.2.4.1 Germany Specialty Generics Market
        • 7.2.4.1.1 Germany Specialty Generics Market by Type
        • 7.2.4.1.2 Germany Specialty Generics Market by Application
        • 7.2.4.1.3 Germany Specialty Generics Market by End Use
      • 7.2.4.2 UK Specialty Generics Market
        • 7.2.4.2.1 UK Specialty Generics Market by Type
        • 7.2.4.2.2 UK Specialty Generics Market by Application
        • 7.2.4.2.3 UK Specialty Generics Market by End Use
      • 7.2.4.3 France Specialty Generics Market
        • 7.2.4.3.1 France Specialty Generics Market by Type
        • 7.2.4.3.2 France Specialty Generics Market by Application
        • 7.2.4.3.3 France Specialty Generics Market by End Use
      • 7.2.4.4 Russia Specialty Generics Market
        • 7.2.4.4.1 Russia Specialty Generics Market by Type
        • 7.2.4.4.2 Russia Specialty Generics Market by Application
        • 7.2.4.4.3 Russia Specialty Generics Market by End Use
      • 7.2.4.5 Spain Specialty Generics Market
        • 7.2.4.5.1 Spain Specialty Generics Market by Type
        • 7.2.4.5.2 Spain Specialty Generics Market by Application
        • 7.2.4.5.3 Spain Specialty Generics Market by End Use
      • 7.2.4.6 Italy Specialty Generics Market
        • 7.2.4.6.1 Italy Specialty Generics Market by Type
        • 7.2.4.6.2 Italy Specialty Generics Market by Application
        • 7.2.4.6.3 Italy Specialty Generics Market by End Use
      • 7.2.4.7 Rest of Europe Specialty Generics Market
        • 7.2.4.7.1 Rest of Europe Specialty Generics Market by Type
        • 7.2.4.7.2 Rest of Europe Specialty Generics Market by Application
        • 7.2.4.7.3 Rest of Europe Specialty Generics Market by End Use
  • 7.3 Asia Pacific Specialty Generics Market
    • 7.3.1 Asia Pacific Specialty Generics Market by Type
      • 7.3.1.1 Asia Pacific Injectables Market by Country
      • 7.3.1.2 Asia Pacific Oral Drugs Market by Country
      • 7.3.1.3 Asia Pacific Others Market by Country
    • 7.3.2 Asia Pacific Specialty Generics Market by Application
      • 7.3.2.1 Asia Pacific Inflammatory conditions Market by Country
      • 7.3.2.2 Asia Pacific Multiple sclerosis Market by Country
      • 7.3.2.3 Asia Pacific Hepatitis C Market by Country
      • 7.3.2.4 Asia Pacific Oncology Market by Country
      • 7.3.2.5 Asia Pacific Others Market by Country
    • 7.3.3 Asia Pacific Specialty Generics Market by End Use
      • 7.3.3.1 Asia Pacific Specialty Pharmacy Market by Country
      • 7.3.3.2 Asia Pacific Retail Pharmacy Market by Country
      • 7.3.3.3 Asia Pacific Hospital Pharmacy Market by Country
    • 7.3.4 Asia Pacific Specialty Generics Market by Country
      • 7.3.4.1 China Specialty Generics Market
        • 7.3.4.1.1 China Specialty Generics Market by Type
        • 7.3.4.1.2 China Specialty Generics Market by Application
        • 7.3.4.1.3 China Specialty Generics Market by End Use
      • 7.3.4.2 Japan Specialty Generics Market
        • 7.3.4.2.1 Japan Specialty Generics Market by Type
        • 7.3.4.2.2 Japan Specialty Generics Market by Application
        • 7.3.4.2.3 Japan Specialty Generics Market by End Use
      • 7.3.4.3 India Specialty Generics Market
        • 7.3.4.3.1 India Specialty Generics Market by Type
        • 7.3.4.3.2 India Specialty Generics Market by Application
        • 7.3.4.3.3 India Specialty Generics Market by End Use
      • 7.3.4.4 South Korea Specialty Generics Market
        • 7.3.4.4.1 South Korea Specialty Generics Market by Type
        • 7.3.4.4.2 South Korea Specialty Generics Market by Application
        • 7.3.4.4.3 South Korea Specialty Generics Market by End Use
      • 7.3.4.5 Singapore Specialty Generics Market
        • 7.3.4.5.1 Singapore Specialty Generics Market by Type
        • 7.3.4.5.2 Singapore Specialty Generics Market by Application
        • 7.3.4.5.3 Singapore Specialty Generics Market by End Use
      • 7.3.4.6 Malaysia Specialty Generics Market
        • 7.3.4.6.1 Malaysia Specialty Generics Market by Type
        • 7.3.4.6.2 Malaysia Specialty Generics Market by Application
        • 7.3.4.6.3 Malaysia Specialty Generics Market by End Use
      • 7.3.4.7 Rest of Asia Pacific Specialty Generics Market
        • 7.3.4.7.1 Rest of Asia Pacific Specialty Generics Market by Type
        • 7.3.4.7.2 Rest of Asia Pacific Specialty Generics Market by Application
        • 7.3.4.7.3 Rest of Asia Pacific Specialty Generics Market by End Use
  • 7.4 LAMEA Specialty Generics Market
    • 7.4.1 LAMEA Specialty Generics Market by Type
      • 7.4.1.1 LAMEA Injectables Market by Country
      • 7.4.1.2 LAMEA Oral Drugs Market by Country
      • 7.4.1.3 LAMEA Others Market by Country
    • 7.4.2 LAMEA Specialty Generics Market by Application
      • 7.4.2.1 LAMEA Inflammatory conditions Market by Country
      • 7.4.2.2 LAMEA Multiple sclerosis Market by Country
      • 7.4.2.3 LAMEA Hepatitis C Market by Country
      • 7.4.2.4 LAMEA Oncology Market by Country
      • 7.4.2.5 LAMEA Others Market by Country
    • 7.4.3 LAMEA Specialty Generics Market by End Use
      • 7.4.3.1 LAMEA Specialty Pharmacy Market by Country
      • 7.4.3.2 LAMEA Retail Pharmacy Market by Country
      • 7.4.3.3 LAMEA Hospital Pharmacy Market by Country
    • 7.4.4 LAMEA Specialty Generics Market by Country
      • 7.4.4.1 Brazil Specialty Generics Market
        • 7.4.4.1.1 Brazil Specialty Generics Market by Type
        • 7.4.4.1.2 Brazil Specialty Generics Market by Application
        • 7.4.4.1.3 Brazil Specialty Generics Market by End Use
      • 7.4.4.2 Argentina Specialty Generics Market
        • 7.4.4.2.1 Argentina Specialty Generics Market by Type
        • 7.4.4.2.2 Argentina Specialty Generics Market by Application
        • 7.4.4.2.3 Argentina Specialty Generics Market by End Use
      • 7.4.4.3 UAE Specialty Generics Market
        • 7.4.4.3.1 UAE Specialty Generics Market by Type
        • 7.4.4.3.2 UAE Specialty Generics Market by Application
        • 7.4.4.3.3 UAE Specialty Generics Market by End Use
      • 7.4.4.4 Saudi Arabia Specialty Generics Market
        • 7.4.4.4.1 Saudi Arabia Specialty Generics Market by Type
        • 7.4.4.4.2 Saudi Arabia Specialty Generics Market by Application
        • 7.4.4.4.3 Saudi Arabia Specialty Generics Market by End Use
      • 7.4.4.5 South Africa Specialty Generics Market
        • 7.4.4.5.1 South Africa Specialty Generics Market by Type
        • 7.4.4.5.2 South Africa Specialty Generics Market by Application
        • 7.4.4.5.3 South Africa Specialty Generics Market by End Use
      • 7.4.4.6 Nigeria Specialty Generics Market
        • 7.4.4.6.1 Nigeria Specialty Generics Market by Type
        • 7.4.4.6.2 Nigeria Specialty Generics Market by Application
        • 7.4.4.6.3 Nigeria Specialty Generics Market by End Use
      • 7.4.4.7 Rest of LAMEA Specialty Generics Market
        • 7.4.4.7.1 Rest of LAMEA Specialty Generics Market by Type
        • 7.4.4.7.2 Rest of LAMEA Specialty Generics Market by Application
        • 7.4.4.7.3 Rest of LAMEA Specialty Generics Market by End Use

Chapter 8. Company Profiles

  • 8.1 Teva Pharmaceutical Industries Ltd.
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Regional Analysis
    • 8.1.4 Research & Development Expenses
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Partnerships, Collaborations, and Agreements:
      • 8.1.5.2 Product Launches and Product Expansions:
  • 8.2 Novartis AG
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental and Regional Analysis
    • 8.2.4 Research & Development Expense
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Partnerships, Collaborations, and Agreements:
      • 8.2.5.2 Acquisition and Mergers:
  • 8.3 Hikma Pharmaceuticals PLC
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental and Regional Analysis
    • 8.3.4 Research & Development Expenses
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
      • 8.3.5.2 Product Launches and Product Expansions:
  • 8.4 Sun Pharmaceutical Industries Ltd.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Regional Analysis
    • 8.4.4 Research & Development Expenses
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Partnerships, Collaborations, and Agreements:
      • 8.4.5.2 Product Launches and Product Expansions:
  • 8.5 Fresenius SE & Co. KGaA
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental and Regional Analysis
    • 8.5.4 Research & Development Expenses
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Acquisition and Mergers:
  • 8.6 Dr. Reddy's Laboratories Ltd.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expense
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Product Launches and Product Expansions:
  • 8.7 Mallinckrodt PLC
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Segmental and Regional Analysis
    • 8.7.4 Research & Development Expense
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Partnerships, Collaborations, and Agreements:
  • 8.8 Bausch Health Companies, Inc
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Segmental and Regional Analysis
    • 8.8.4 Research & Development Expense
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Partnerships, Collaborations, and Agreements:
  • 8.9 Viatris, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Segmental Analysis
    • 8.9.4 Research & Development Expense
    • 8.9.5 Recent strategies and developments:
      • 8.9.5.1 Partnerships, Collaborations, and Agreements:
  • 8.10. Apotex, Inc.
    • 8.10.1 Company Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제